Early Detection of Lung Cancer

The patients who are enrolled in this study are typically just thought of as incurable in the current conventional sense, so the fact that we saw these responses was really exciting, because this suggests this strategy could be adopted for very challenging incurable diseases.”

—Oncologist Won Jin Ho, of the Johns Hopkins Kimmel Cancer Center, describing a new study showing that a combination of the kinase-inhibitor drug cabozantinib and the immunotherapy drug nivolumab can make curative surgery possible in some liver cancer patients who would normally not be considered surgery candidates. The team reported on their findings in July in Nature Cancer.